207 related articles for article (PubMed ID: 15056149)
21. Soft tissue augmentation with PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy.
Serra MS; Gonçalves LZ; Ramos-e-Silva M
Int J STD AIDS; 2015 Mar; 26(4):279-84. PubMed ID: 24855130
[TBL] [Abstract][Full Text] [Related]
22. Approaches to treatment of HIV facial lipoatrophy.
Jones D
Skin Therapy Lett; 2005 Nov; 10(9):5-7. PubMed ID: 16292459
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of injectable calcium hydroxylapatite for the treatment of facial lipoatrophy associated with human immunodeficiency virus.
Carruthers A; Carruthers J
Dermatol Surg; 2008 Nov; 34(11):1486-99. PubMed ID: 18811715
[TBL] [Abstract][Full Text] [Related]
24. Restorative interventions for HIV facial lipoatrophy.
Carey D; Liew S; Emery S
AIDS Rev; 2008; 10(2):116-24. PubMed ID: 18615122
[TBL] [Abstract][Full Text] [Related]
25. Treatment of facial lipoatrophy via autologous fat transfer.
Cohen G; Treherne A
J Drugs Dermatol; 2009 May; 8(5):486-9. PubMed ID: 19537373
[TBL] [Abstract][Full Text] [Related]
26. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential.
Narins RS; Beer K
Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):77S-84S. PubMed ID: 16936547
[TBL] [Abstract][Full Text] [Related]
27. [Injectable soft tissue fillers: are they medical devices or drugs? Implications for HIV lipodystrophy].
Nikolic DS; Balagué N; Campanelli A; Elias B; Calmy A; Toutous-Trellu L
Rev Med Suisse; 2012 Apr; 8(335):747-53. PubMed ID: 22545496
[TBL] [Abstract][Full Text] [Related]
28. Minimizing discomfort during the injection of Radiesse with the use of either local anesthetic or ice.
Comite S; Greene A; Cieszynski SA; Zaroovabeli P; Marks K
Dermatol Online J; 2007 Jul; 13(3):5. PubMed ID: 18328199
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
[TBL] [Abstract][Full Text] [Related]
30. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
[TBL] [Abstract][Full Text] [Related]
31. Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients.
Pavicic T; Ruzicka T; Korting HC; Gauglitz G
J Drugs Dermatol; 2010 Jun; 9(6):690-5. PubMed ID: 20645533
[TBL] [Abstract][Full Text] [Related]
32. Facial fat volume in HIV-infected patients with lipoatrophy.
Yang Y; Sitoh YY; Oo Tha N; Paton NI
Antivir Ther; 2005; 10(4):575-81. PubMed ID: 16038484
[TBL] [Abstract][Full Text] [Related]
33. Patient satisfaction following Bio-Alcamid injection for facial contour defects.
George DA; Erel E; Waters R
J Plast Reconstr Aesthet Surg; 2012 Dec; 65(12):1622-6. PubMed ID: 22749703
[TBL] [Abstract][Full Text] [Related]
34. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of injectable CaHA for the treatment of mid-face volume loss.
Beer K; Yohn M; Cohen JL
J Drugs Dermatol; 2008 Apr; 7(4):359-66. PubMed ID: 18459517
[TBL] [Abstract][Full Text] [Related]
36. Cost consequences of HIV-associated lipoatrophy.
Hornberger J; Rajagopalan R; Shewade A; Loutfy MR
AIDS Care; 2009 May; 21(5):664-71. PubMed ID: 19444676
[TBL] [Abstract][Full Text] [Related]
37. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
[TBL] [Abstract][Full Text] [Related]
38. Relationship between lipoatrophy and quality of life.
Echavez M; Horstman W
AIDS Read; 2005 Jul; 15(7):369-75. PubMed ID: 16044579
[TBL] [Abstract][Full Text] [Related]
39. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
Mest DR; Humble GM
Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
[TBL] [Abstract][Full Text] [Related]
40. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires.
Warde M; Gragnani A; Gomes H; Hochman B; Ferreira LM
Int J STD AIDS; 2011 Oct; 22(10):596-9. PubMed ID: 21998182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
